The Indian Council of Medical Research (ICMR) and Panacea Biotec have announced the initiation of the first-ever Phase 3 clinical trial for a dengue vaccine in India. This landmark trial will evaluate the efficacy of India's indigenous tetravalent dengue vaccine, DengiAll, developed by Panac
Singapore, February 27: Takeda (TSE:4502/NYSE:TAK) today announced a strategic partnership with Biological E. Limited, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003. The partnership marks a crucial step in the fight against the global publ
Two companies are conducting trials to develop dengue vaccine, Director General, Indian Council of Medical Research Dr Rajeev Bahl told ANI on Tuesday.
New Delhi [India], September 30 (ANI): Indian Council for Medical Research Director-General Balram Bhargava on Thursday said that many companies have conducted their phase one trials of dengue vaccines abroad and that the Health Ministry is planning to do more rigorous trials.